


Supplementary Table S1. Qualitative agreement in infliximab and adalimumab concentrations before and after the correction of the homogeneous mobility shift assay.

| INFLIXIMAB | | | | | |
|---------------------|-----------------|-----------------------|-------------|-------|---------------------------|
| | | HMSA corrected | | | |
| <i>>5 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 22 | 0 | 22 | Negative agreement = 39% |
| | Therapeutic | 34 | 262 | 296 | Positive agreement = 100% |
| | Total | 56 | 262 | 318 | Total agreement = 89% |
| | | HMSA corrected | | | |
| <i>>7 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 44 | 1 | 45 | Negative agreement = 49% |
| | Therapeutic | 45 | 228 | 273 | Positive agreement = 100% |
| | Total | 89 | 229 | 318 | Total agreement = 86% |
| | | HMSA corrected | | | |
| <i>>10 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 84 | 0 | 84 | Negative agreement = 52% |
| | Therapeutic | 78 | 156 | 234 | Positive agreement = 100% |
| | Total | 162 | 156 | 318 | Total agreement = 75% |
| ADALIMUMAB | | | | | |
| | | HMSA corrected | | | |
| <i>>5 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 20 | 0 | 20 | Negative agreement = 43% |
| | Therapeutic | 26 | 292 | 318 | Positive agreement = 100% |
| | Total | 46 | 292 | 338 | Total agreement = 92% |
| | | HMSA corrected | | | |
| <i>>7 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 39 | 0 | 39 | Negative agreement = 44% |
| | Therapeutic | 49 | 250 | 299 | Positive agreement = 100% |
| | Total | 88 | 250 | 338 | Total agreement = 86% |
| | | HMSA corrected | | | |
| <i>>10 µg/ml</i> | | Sub-therapeutic | Therapeutic | Total | Percentage agreement |
| HMSA | Sub-therapeutic | 77 | 0 | 77 | Negative agreement = 48% |
| | Therapeutic | 84 | 177 | 261 | Positive agreement = 100% |
| | Total | 161 | 177 | 338 | Total agreement = 75% |

HMSA: homogeneous mobility shift assay.

Supplementary Figure S1. Receiver operator curve analysis for adalimumab concentrations at last affected TDM before (A) and after (B) the implementation of corrected measures stratifying patients with or without treatment failure.



HMSA: homogeneous mobility shift assay; AUC: area under the curve; CI: confidence intervals.